Hans J. Salwender
Asklepios Klinik Altona And Asklepios Klinik St. Georg
St. Georg, HH, Germany
St. Georg, HH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 98 publications
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.
Journal: Nature medicine
Published: July 06, 2026
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 08, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 21, 2026
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.
Journal: Lancet (London, England)
Published: February 19, 2026
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.
Journal: American journal of hematology
Published: December 02, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.
Journal: European journal of haematology
Published: July 07, 2025
Prospective systematic classification of causes of death in the course of multiple myeloma.
Journal: Blood cancer journal
Published: July 02, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial.
Journal: Cardio-oncology (London, England)
Published: April 06, 2025
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 09, 2024
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours.
Journal: Journal of cancer research and clinical oncology
Published: December 02, 2024
Last Updated: 09/26/2026